It is determined by the pharmacokinetics of each specific peptide, the therapeutic goal, and the cycle structure prescribed
If this were the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasized
Caution is warranted when: Weight is stable but distress is high Fatigue, hormonal symptoms, or GI issues are the main concern Under-eating or nutrient deficiency is already present Muscle and bone mass are low, or frailty risk is high There is sarcopenia risk, especially in older adults BMI is in the normal range and use would be off-label without a clear medical rationale In these cases, building nutrition adequacy and strength first may improve symptoms and long-term health more than appetite suppression
Then, they can change treatment plans to get the best results
However, to achieve safe and meaningful results from peptide therapy, your provider must not only understand the science behind peptides, but also understand your unique biology